In order to better predict responses to specific therapies, breast cancer patients are now stratified into 6 molecular subtypes – luminal A, luminal B, Her2-enriched, basal-like, normal-like and claudin-low5. This evidence concerns the gene ERBB2 and breast carcinoma.